163 related articles for article (PubMed ID: 18849150)
1. Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables.
Acosta FJ; Bosch E; Sarmiento G; Juanes N; Caballero-Hidalgo A; Mayans T
Schizophr Res; 2009 Feb; 107(2-3):213-7. PubMed ID: 18849150
[TBL] [Abstract][Full Text] [Related]
2. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia.
Remington G; Kwon J; Collins A; Laporte D; Mann S; Christensen B
Schizophr Res; 2007 Feb; 90(1-3):229-37. PubMed ID: 17208414
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®).
Acosta FJ; Ramallo-Fariña Y; Bosch E; Mayans T; Rodríguez CJ; Caravaca A
Schizophr Res; 2013 May; 146(1-3):196-200. PubMed ID: 23474024
[TBL] [Abstract][Full Text] [Related]
4. Treatment adherence and insight in schizophrenia.
Bitter I; Fehér L; Tényi T; Czobor P
Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
[TBL] [Abstract][Full Text] [Related]
5. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
6. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.
Brain C; Allerby K; Sameby B; Quinlan P; Joas E; Karilampi U; Lindström E; Eberhard J; Burns T; Waern M
Eur Neuropsychopharmacol; 2013 Dec; 23(12):1754-62. PubMed ID: 24091164
[TBL] [Abstract][Full Text] [Related]
7. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia.
Yang J; Ko YH; Paik JW; Lee MS; Han C; Joe SH; Jung IK; Jung HG; Kim SH
Schizophr Res; 2012 Feb; 134(2-3):226-31. PubMed ID: 22133906
[TBL] [Abstract][Full Text] [Related]
8. Twelve months of electronic monitoring (MEMS®) in the Swedish COAST-study: a comparison of methods for the measurement of adherence in schizophrenia.
Brain C; Sameby B; Allerby K; Lindström E; Eberhard J; Burns T; Waern M
Eur Neuropsychopharmacol; 2014 Feb; 24(2):215-22. PubMed ID: 24359935
[TBL] [Abstract][Full Text] [Related]
9. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
Byerly MJ; Nakonezny PA; Rush AJ
Schizophr Res; 2008 Mar; 100(1-3):60-9. PubMed ID: 18255269
[TBL] [Abstract][Full Text] [Related]
10. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
Stanković Z; Britvić D; Vuković O; Ille T
Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
[TBL] [Abstract][Full Text] [Related]
11. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
Linden M; Scheel T; Eich FX
J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS®): A six-month post-discharge prospective study.
Misdrahi D; Tessier A; Husky M; Lange AC; Vrijens B; Llorca PM; Baylé FJ
Schizophr Res; 2018 Mar; 193():114-118. PubMed ID: 28663027
[TBL] [Abstract][Full Text] [Related]
13. Medication noncompliance and substance abuse among patients with schizophrenia.
Owen RR; Fischer EP; Booth BM; Cuffel BJ
Psychiatr Serv; 1996 Aug; 47(8):853-8. PubMed ID: 8837158
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic alliance, a stake in schizophrenia].
Charpentier A; Goudemand M; Thomas P
Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
[TBL] [Abstract][Full Text] [Related]
15. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
[TBL] [Abstract][Full Text] [Related]
16. Should full adherence be a necessary goal in schizophrenia? Full versus non-full adherence to antipsychotic treatment.
Acosta FJ; Ramallo-Fariña Y; Siris SG
Compr Psychiatry; 2014 Jan; 55(1):33-9. PubMed ID: 24183886
[TBL] [Abstract][Full Text] [Related]
17. Overview of partial compliance.
Marder SR
J Clin Psychiatry; 2003; 64 Suppl 16():3-9. PubMed ID: 14680412
[TBL] [Abstract][Full Text] [Related]
18. [Drug compliance and health locus of control in schizophrenia].
Combes C; Feral F
Encephale; 2011 May; 37 Suppl 1():S11-8. PubMed ID: 21600328
[TBL] [Abstract][Full Text] [Related]
19. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders.
Duncan JC; Rogers R
J Forensic Sci; 1998 Nov; 43(6):1133-7. PubMed ID: 9846389
[TBL] [Abstract][Full Text] [Related]
20. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia.
Byerly M; Fisher R; Whatley K; Holland R; Varghese F; Carmody T; Magouirk B; Rush AJ
Psychiatry Res; 2005 Feb; 133(2-3):129-33. PubMed ID: 15740989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
